AngioDynamics (NASDAQ:ANGO) Announces Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.11, Yahoo Finance reports. The company had revenue of $71.00 million for the quarter, compared to the consensus estimate of $70.86 million. AngioDynamics had a negative return on equity of 3.48% and a negative net margin of 60.21%. AngioDynamics’s quarterly revenue was down 22.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.02 EPS. AngioDynamics updated its FY25 guidance to ($0.42)-($0.38) EPS and its FY 2025 guidance to -0.420–0.380 EPS.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $7.51 on Wednesday. The stock has a market capitalization of $300.85 million, a P/E ratio of -1.55 and a beta of 0.66. AngioDynamics has a 1-year low of $5.26 and a 1-year high of $9.77. The business has a fifty day moving average price of $6.05 and a 200 day moving average price of $6.05.

Analyst Ratings Changes

A number of research firms have recently issued reports on ANGO. Oppenheimer raised AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Friday, April 5th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $13.25.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.